MyCartis Announces Appointment of Dr. Jan Groen to Its Board of Directors

GHENT, Belgium and LAUSANNE, Switzerland, April 9, 2015 /PRNewswire/ --

~ CEO of MDxHealth becomes new independent director ~

MyCartis NV today announced that Dr. Jan Groen, an accomplished diagnostics executive, was elected to the company's Board of Directors. Dr. Groen currently serves as president and chief executive officer of MDxHealth, a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. With his appointment, the size of MyCartis' Board increases to 7 members.

Dr. Groen has a distinguished career in the clinical diagnostic and the life sciences industry. Prior to joining MDxHealth in 2010, he was president and chief operating officer of Agendia, Inc., a privately held, leading molecular diagnostics company that develops and markets genomic diagnostic products a genomic disease management company From 1991 until 1993, Dr. Groen was vice president of Focus Diagnostics Inc., a clinical diagnostic company that was acquired by Quest Diagnostics in 2006. He has been a member of the IBL Internationals Board, an in vitro diagnostic company acquired by Tecan in 2014.  

"Jan is a great addition to our Board," said Mr. Paul Ladestein, CEO of MyCartis. "His international diagnostic experience and insights, built over 25 years, will be instrumental to help us build and grow MyCartis' highly innovative multiplex business. We are looking forward to working with him."

Jan's vision on the role of multiplex biomarker analysis in oncology can be read in this blog.

About MyCartis

MyCartis™ is dedicated to changing healthcare through a personalized approach. Operating on the forefront of technology, it is MyCartis' ambition to radically change healthcare through its next generation multiplex biomarker analysis platform.

The Evalution™ platform and its applications provide researchers and pharmaceutical companies with q a quick, accurate, and cost-effective access to proteomic and genomic information.

This combination makes personalized treatments and the development of personalized medicine possible, resulting in a better quality of life for everyone.

Together with partners that share the company's vision, MyCartis has the ambition to accelerate innovation in the fields of disease care and prevention and personal health management for everyone.

MyCartis has offices in Ghent (Belgium) and Lausanne (Switzerland). For more information about MyCartis, Evalution™ or the partner program, please visit http://www.mycartis.net

SOURCE MyCartis